Opus Genetics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
29.1%projected annual EPS growth
Analyst Coverage
18analysts covering
FY Revenue (est.)
$15.2Mnext fiscal year
FY EPS (est.)
-$1.00next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| OPGx-LCA5 Phase 3 Pivotal Trial Dosing Initiation | 31 Dec 2026 |
| OPGx-RDH12 Phase 1/2 Clinical Trial Initiation | 31 Dec 2026 |
| OPGx-MERTK Phase 1/2 Clinical Trial Initiation | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
OPGx-LCA5 Phase 3 Dosing Initiation QuarterlyTarget: Initiate dosing in the pivotal Phase 3 trial in Q4 2026
OPGx-BEST1 Phase 1/2 Topline Data Readout QuarterlyTarget: Release 3-month topline data from Cohort 1 in September 2026
OPGx-RDH12 Clinical Trial Initiation QuarterlyTarget: Initiate clinical testing in the U.S. in Q4 2026
OPGx-MERTK Clinical Trial Initiation QuarterlyTarget: Initiate clinical testing at Cleveland Clinic Abu Dhabi in Q1 2027
OPGx-RHO Clinical Trial Initiation QuarterlyTarget: Initiate clinical testing globally in H2 2027
Watch Items
- Cash Runway and Capital SufficiencyTrigger: Cash balance falling below $40 million without additional non-dilutive or debt tranches drawnAction: Evaluate drawing down additional tranches under the $155 million Oberland Capital facility or securing further non-dilutive patient advocacy grants.
- OPGx-BEST1 Safety and Efficacy SignalsTrigger: Occurrence of any serious ocular adverse events or lack of visual acuity improvement in the September 2026 readoutAction: Re-evaluate dosing protocols for Cohort 2 and consult the Medical Advisory Board regarding vector safety.
- OPGx-LCA5 Phase 3 Regulatory AlignmentTrigger: FDA feedback altering the streamlined single-trial design under the Rare Disease Evidence Principles (RDEP) programAction: Adjust clinical trial design, timeline, and budget projections to accommodate potential multi-trial requirements.
Research as of 20 Jun 2026